loncastuximab
adc therapeutics
['lotis-2', 'cml', 'adctherap']
attending #17icml? don't miss 's presentation of updated results from our lotis-2 pivotal phase 2 clinical trial evaluating our cd19-targeted #antibodydrugconjugate. more details here: 
Leading the development & commercialization of next-generation antibody drug conjugates with highly potent and targeted pyrrolobenzodiazepine dimer technology